Companies in #Idiopathic Pulmonary Fibrosis

Celea Therapeutics is a clinical-stage respiratory therapeutics company spun out of PureTech Health in August 2025. Lead program is deupirfenidone (LYT-100), a Phase 3-ready deuterated pirfenidone candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic and inflammatory lung conditions.

Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology, and fibrotic disease. The company was incorporated in 2009 as Pipeline Therapeutics and renamed Contineum Therapeutics in November 2023 to reflect its expansion into fibrotic indications, and is based in San Diego, California. Its two clinical programs target de-risked mechanisms with existing human data: PIPE-791, an LPA1 receptor antagonist being developed in idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, a selective M1 muscarinic receptor antagonist licensed to Johnson & Johnson as JNJ-5120 and in development for major depressive disorder and remyelination in multiple sclerosis. Contineum listed on Nasdaq in April 2024 and carries a substantial cash balance relative to its operating burn, which leaves the equity sensitive to clinical readouts on its partnered and wholly owned programs rather than to near-term financing risk.

Gyre Therapeutics is a commercial-stage biopharmaceutical company developing small-molecule therapies for organ fibrosis and inflammatory disease, operating in both the United States and China. Through its majority-owned subsidiary Gyre Pharmaceuticals it markets ETUARY (pirfenidone capsule), the first approved treatment for idiopathic pulmonary fibrosis in China, and is advancing F351 (hydronidone) — a structurally modified pirfenidone derivative targeting TGF-beta1 signalling — for chronic hepatitis B-associated liver fibrosis in China, where the NDA was accepted with priority review in 2026, and for MASH-associated liver fibrosis in the United States. A May 2026 all-stock acquisition of Cullgen added a targeted protein degrader and degrader-antibody conjugate discovery platform. The company is headquartered in San Diego and majority-owned by GNI USA.

MannKind is a biopharmaceutical company focused on inhaled therapeutic products for endocrine and orphan lung diseases, built on its proprietary Technosphere dry-powder inhalation platform. Its commercial portfolio includes Afrezza, the only FDA-approved inhaled mealtime insulin, and the V-Go wearable insulin delivery device; the company also manufactures Tyvaso DPI, an inhaled treprostinil powder commercialized by United Therapeutics, from which MannKind earns royalties and manufacturing revenue, and it has expanded into heart-failure fluid management with FUROSCIX and its ReadyFlow autoinjector. The pipeline extends the same platform into interstitial lung disease with MNKD-201 (inhaled nintedanib), which reported positive Phase 1b data in 2026, and into metabolic disease through a September 2026 licensing and collaboration agreement with Rose Pharma for ROSE-010, an inhaled rapid-acting GLP-1 for weight management. Founded in February 1991 by Alfred E. Mann and headquartered in Danbury, Connecticut, the company reported second-quarter 2026 revenue of $109.4 million, up 43% year over year, at a gross margin above 79%, while still recording a small operating loss and negative free cash flow. A Phase 3 program in nontuberculous mycobacterial lung disease with nebulized clofazimine (MNKD-101) was discontinued for futility in November 2025, with the NTM effort redirected to an earlier dry-powder formulation.